Publications dans lesquelles il/elle collabore avec Ana Belén Fernández Martínez (11)

2015

  1. VIP induces NF-κB1-nuclear localisation through different signalling pathways in human tumour and non-tumour prostate cells

    Cellular Signalling, Vol. 27, Núm. 2, pp. 236-244

2014

  1. Signalling pathways involved in antitumoral effects of VIP in human renal cell carcinoma A498 cells: VIP induction of p53 expression

    International Journal of Biochemistry and Cell Biology, Vol. 53, pp. 295-301

2013

  1. Inhibitory effects of antagonists of growth hormone-releasing hormone on growth and invasiveness of PC3 human prostate cancer

    International Journal of Cancer, Vol. 132, Núm. 4, pp. 755-765

2012

  1. Overexpression of vasoactive intestinal peptide receptors and cyclooxygenase-2 in human prostate cancer. Analysis of potential prognostic relevance

    Histology and Histopathology, Vol. 27, Núm. 8, pp. 1093-1101

  2. Vasoactive intestinal peptide (VIP) inhibits human renal cell carcinoma proliferation

    Biochimica et Biophysica Acta - Molecular Cell Research, Vol. 1823, Núm. 10, pp. 1676-1685

2010

  1. Nuclear localization of vasoactive intestinal peptide (VIP) receptors in human breast cancer

    Peptides, Vol. 31, Núm. 11, pp. 2035-2045

  2. Vasoactive intestinal peptide (VIP) induces malignant transformation of the human prostate epithelial cell line RWPE-1

    Cancer Letters, Vol. 299, Núm. 1, pp. 11-21

2009

  1. Multifunctional role of VIP in prostate cancer progression in a xenograft model: Suppression by curcumin and COX-2 inhibitor NS-398

    Peptides, Vol. 30, Núm. 12, pp. 2357-2364

  2. Vasoactive intestinal peptide behaves as a pro-metastatic factor in human prostate cancer cells

    Prostate, Vol. 69, Núm. 7, pp. 774-786

2007

  1. Vasoactive intestinal peptide induces cyclooxygenase-2 expression through nuclear factor-κB in human prostate cell lines. Differential time-dependent responses in cancer progression

    Molecular and Cellular Endocrinology, Vol. 270, Núm. 1-2, pp. 8-16

2005

  1. Expression of vasoactive intestinal peptide and functional VIP receptors in human prostate cancer: antagonistic action of a growth-hormone-releasing hormone analog.

    International journal of oncology, Vol. 26, Núm. 6, pp. 1629-1635